Nintedanib is a targeted therapy used in the treatment of idiopathic pulmonary fibrosis (IPF) and certain progressive fibrosing interstitial lung diseases, along with select cancer indications. India’s pharmaceutical sector offers a growing range of Nintedanib brands, manufactured under strict quality standards and made available at competitive prices compared to global markets. These brands are exported and supplied across various countries through trusted PCD pharma franchise and third-party manufacturing partners. Biophar Lifesciences is a reliable name in this space, offering quality-assured Nintedanib formulations backed by consistent supply and regulatory compliance for healthcare businesses worldwide.
